AgeX Therapeutics Q3 EPS $(0.14) Down From $(0.06) YoY, Sales $67.00K Up From $9.00K YoY
Portfolio Pulse from Benzinga Newsdesk
AgeX Therapeutics reported a Q3 EPS loss of $(0.14), a significant decrease from the $(0.06) loss per share in the same quarter last year. However, sales saw a substantial increase to $67.00K, up from $9.00K in the same period last year, marking a 644.44% increase.
November 14, 2023 | 9:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AgeX Therapeutics experienced a larger EPS loss in Q3 compared to last year, but reported a significant increase in sales.
The widened loss per share could concern investors about the company's profitability, potentially putting downward pressure on the stock price. However, the substantial increase in sales indicates significant revenue growth, which could counterbalance the negative impact of the increased losses. The net effect on the stock price is uncertain, hence a neutral score is given.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100